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Abstract
Background: Metastatic melanoma is a highly aggressive skin cancer and currently resistant to systemic therapy.
Melanomas may involve genetic, epigenetic and metabolic abnormalities. Evidence is emerging that epigenetic changes
might play a significant role in tumor cell plasticity and metastatic phenotype of melanoma cells.
Principal findings: In this study, we developed a systematic approach to identify genes implicated in melanoma
progression. To do this, we used the Affymetrix GeneChip Arrays to screen 34,000 mouse transcripts in melan-a
melanocytes, 4C pre-malignant melanocytes, 4C112 non-metastatic and 4C11+ metastatic melanoma cell lines. The
genome-wide association studies revealed pathways commonly over-represented in the transition from immortalized to
pre-malignant stage, and under-represented in the transition from non-metastatic to metastatic stage. Additionally, the
treatment of cells with 10 mM 5-aza-29-deoxycytidine (5AzaCdR) for 48 hours allowed us to identify genes differentially re-
expressed at specific stages of melan-a malignant transformation. Treatment of human primary melanocytes with the
demethylating agent 5AzaCdR in combination to the histone deacetylase inhibitor Trichostatin A (TSA) revealed changes on
melanocyte morphology and gene expression which could be an indicator of epigenetic flexibility in normal melanocytes.
Moreover, changes on gene expression recognized by affecting the melanocyte biology (NDRG2 and VDR), phenotype of
metastatic melanoma cells (HSPB1 and SERPINE1) and response to cancer therapy (CTCF, NSD1 and SRC) were found when
Mel-2 and/or Mel-3-derived patient metastases were exposed to 5AzaCdR plus TSA treatment. Hierarchical clustering and
network analyses in a panel of five patient-derived metastatic melanoma cells showed gene interactions that have never
been described in melanomas.
Significance: Despite the heterogeneity observed in melanomas, this study demonstrates the utility of our murine
melanoma progression model to identify molecular markers commonly perturbed in metastasis. Additionally, the novel
gene expression signature identified here may be useful in the future into a model more closely related to translational
research.
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Introduction
Metastatic melanoma is a highly aggressive and drug-resistant
skin cancer and has a poor prognosis, with a 1-year survival rate
ranging from 33% to 62% [1,2]. The current methodology to
diagnose primary melanomas is based on histomorphologic
features, however such classification system has remained of
limited clinical relevance once metastases have developed. The
current prevailing opinion is that melanomas are more variable at
the molecular level than can be observed macro/microscopically
[3,4]. For anti-melanoma strategies to be successful, it is important
the better understanding about the molecular mechanisms that
mediate phenotype-switching in melanomas, since these biomark-
ers could drive metastatic disease. According to the genetic model
to explain the pathways towards metastasis, the acquisition of
mutations that promote invasiveness leads to cells migrating away
from the primary tumor before arriving in a new site where they
divide to form a new metastasis. As the genetic lesions are
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irreversible, metastases will be genetically distinct from the
primary tumor. In contrast of this, there is a hypothesis which
suggests that metastases arise because of microenvironment-driven
changes to a cell’s phenotype, leading to some cells acquiring a
slow proliferating, stem cell-like phenotype with invasive potential.
Given the appropriate signals, these cells will migrate to find a new
niche where a different microenvironment will lead to either a
resumption of proliferation and formation of a new metastasis or
dormancy [5]. As the epigenetic modifications can be modulated
by changes in the environment, leading to a reprogramming of
gene expression patterns in mammals [6,7], it is plausible to
hypothesize that there is a biological relationship between
epigenetics and microenvironment-driven changes in gene expres-
sion, which would lead to a phenotype-switching in melanomas. In
fact, it has become clear that a dynamic reprogramming in
epigenetic marks has been positively correlated with aberrant gene
expression during melanocytic neoplasia, including our model of
study [8–11]. Epigenetic information is propagated during somatic
cell divisions, and is critical for preserving gene expression patterns
and cellular identity. Epigenetic regulation of gene expression
involves the interplay of DNA methylation, histone modifications,
nucleosome occupancy, and microRNAs. DNA methylation
patterns are tightly correlated with chromatin architecture. Active
regions of the chromatin, which enable gene expression, are
associated with hypomethylated DNA, whereas hypermethylated
DNA is packaged in inactive chromatin. Histone deacetylation is a
global mark of gene silencing. The interrelation between DNA
methyltransferases (DNMTs) and histone deacetylases (HDACs)
associated with the dynamic reversibility of epigenetic signatures in
somatic cells, has been offered opportunities for testing drugs that
can re-express critical silenced-genes in cancer [12–13]. The main
purpose of our research was to identify novel markers in early and
later stages of melan-a malignant transformation. The molecular
markers deregulated earlier in melan-a malignant transformation
could provide insights into the aetiology and pathogenesis of
melanomas. In addition, they would be useful to predict a
functional phenotype associated with metastasis. Apart from this,
the molecular markers specifically deregulated at metastatic stage
could confer selective clonal growth advantage. Here, we used the
high-throughput Affymetrix microarray approach to conduct
class-comparison experiments to identify significantly up- and
down-regulated genes in each transition of malignant transforma-
tion of melan-a mouse melanocyte lineage: from melan-a to 4C,
4C to 4C112, and 4C112 to 4C11+ cells. The 4C (pre-malignant
melanocytes), 4C112 (non-metastatic melanoma) and 4C11+
(metastatic melanoma) cell lines were established after sequential
detachment/re-adhesion cycles of melan-a melanocytes. Next, the
class-comparison experiments were done in melan-a, 4C, 4C112
and 4C11+ cells previously exposed to the demethylating agent 5-
aza-29-deoxycytidine (5AzaCdR). Genome-wide association stud-
ies allowed us to identify candidate down-regulated genes whose
expression could be modulated, directly or indirectly, by 5AzaCdR
treatment at several stages of melanoma progression. A mining
gene expression signature was found and validated in human
specimens untreated and previously treated with 5AzaCdR in
combination to the HDAC inhibitor Trichostatin A (TSA). Our
data open new avenues for the detection of early melanocytic
lesions with high risk for metastasis, meanwhile provide data which
might be used in the future for the incorporation of new
metastasis-related biomarkers into a model more closely related
to translational research.
Results
Tumorigenicity and Metastatic Capabilities Were
Acquired by melan-a Melanocytes after Detachment/
Re-adhesion Cycles
The metastatic capacity of a melanoma cell subpopulation
almost always results in the successful of this neoplastic disease, as
evaluated by growing mortality rates worldwide in patients with
stage IV melanomas (American Joint Committee on Cancer) [2].
Based on this, we first investigated whether cell lines established
from melan-a melanocytes after detachment/re-adhesion cycles
showed tumorigenicity property. As previously described, melan-a
and 4C melanocyte lineages were not able to grow as tumors when
inoculated subcutaneously into C57Bl6 syngeneic mice, whereas
4C112 and 4C11+ cell lines showed tumorigenic potential
[14,15]. Based on the in vivo growth profile, we characterized the
4C112 and 4C11+ cell lines as slow- and fast-growing melano-
mas, respectively, as evaluated by differences in latency times for
tumor appearance (P,0.01) (Figure 1A). We next evaluated
whether 4C112 and 4C11+ melanoma cell lines presented
metastatic capacity. Using C57Bl6 syngeneic mice, 4C11+
melanoma cell line was shown to be able to grow as macrometa-
static pulmonary foci, as evaluated by tumor multiplicity
(P,0.0001) (Figure 1B). Importantly, animals inoculated intra-
venously with 4C11+ melanoma cell line (2.5x105 cells per mouse)
displayed overall survival rates of 30 days (P,0.0001) (Figure 1C).
Karyotype Evolution
The karyotypic instability can act as an indicator of cancer
aggressiveness [16]. As such, we next analyzed karyotypic
aberrations that accompanied the tumorigenic conversion of
melan-a melanocyte lineage. It is worth mentioning that melan-a is
a cell line that was first described as having a normal diploid
karyotype [14]. In addition, melan-a cell line displayed no
structural chromosomal abnormalities [17]. In this article,
evaluation of chromosomal abnormalities of well-established
melanoma cell lines was performed using spectral karyotyping
(SKY). Twenty metaphases per cell line examined were analyzed.
In general, the results of our chromosome analyses combined with
the findings previously reported by Silva et al [17] revealed specific
non-random structural abnormalities in chromosomes 6, 8, 11, 14,
15, and X in pre-malignant melanocytes and early melanomas (4C
and 4C112 cell lines, respectively). Importantly, here we are
showing that the tumorigenic phenotype was marked by the
appearance of a unique translocation of T[7;X], which was seen in
6 of 20 metaphases examined. Besides that, the 4C11+ metastatic
melanoma cell line displayed a complex pattern of numerical and
structural aberrations that may contain potential pathological
consequences. Such metastasis-related aberrations could readily be
distinguished by imbalances in the number of chromosomes,
Robertsonian fusions involving the chromosomes 8 and 12, and
less centromere fragments than 4C112 non-metastatic melanoma
cell line as well (P,0.0001) (Table 1, Figure S1).
Gene Expression Profiles of melan-a Melanocytes and
melan-a-Derived Cell Lines Revealed Pathways
Commonly Perturbed in Pre-Malignant Melanocytes and
Metastatic Melanomas
As the first step in identifying up- and down-regulated genes
associated with melan-a malignant transformation and melanoma
progression, we identified significantly differentially expressed
genes with mRNA extracted from melan-a, 4C, 4C11–– and
4C11+ cell monolayers. The high-throughput Affymetrix micro-
Novel Candidate Biomarkers in Melanomas
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array approach was used as a platform screening (GeneChip
Mouse Genome 430_2.0, format 49; Affymetrix Inc., Santa Clara,
CA). In the chosen arrays, there are 45,101 probe sets designed to
investigate approximately 34,000 mouse transcripts (the whole
genome from Mus musculus). The experiments were carried out in
three biological replicates. Class-comparison experiments were
performed, and transcripts were selected as statistically significant
by the unpairwise two-class SAM analysis (FDR and Q-
values,0.05) by using 700 random permutations as follows: I)
gene expression profile of the parental melan-a melanocyte lineage
versus its 4C pre-malignant melanocyte counterpart: 528 up- and
573 down-regulated genes in 4C pre-malignant melanocytes when
compared with melan-a melanocyte lineage (stage I of melan-a
malignant transformation); II) gene expression profile of 4C pre-
malignant melanocyte lineage versus its 4C112 non-metastatic
melanoma cell counterpart: 112 up- and 51 down-regulated genes
in 4C112 non-metastatic melanoma cell line when compared with
4C pre-malignant melanocyte lineage (stage II of melan-a
malignant transformation); III) gene expression profile of 4C112
non-metastatic melanoma cell line versus its 4C11+ metastatic
melanoma cell counterpart: 1294 up- and 1387 down-regulated
genes in 4C11+ metastatic melanoma cell line when compared
with 4C112 non-metastatic melanoma cell (stage III of melan-a
malignant transformation) (Figure 2A). PANTHER software was
used to determine the pathway profiles deregulated in the course
of melan-a malignant transformation. Therefore, we investigated
whether the proteins encoded by the genes identified as
differentially expressed during the establishment of a melanoma-
like phenotype were connected in known protein interaction
signaling pathways. Following detailed manual annotation, the
resulting pathways were ranked according to the number of genes
involved in each pathway. Within the group corresponding to the
transition from melan-a to 4C, representative genes from 22 and
32 pathways had undergone up- and down-regulation, respective-
ly. Besides that, within the group corresponding to 4C to 4C112
transition, we observed that representative genes from 3 and 5
pathways had undergone up- and down-regulation, respectively.
In addition, representative genes from 39 and 37 pathways had
undergone up- and down-regulation, respectively, within the
group corresponding to 4C112 to 4C11+ transition (Figure 2B).
Additionally, since we have observed no intersection between up-
and down-regulated genes within each group (Figure 2A) the
presence of a switch of genes was found for pathways within the
groups ma versus 4C, and 4C112 versus 4C11+ as follows: I) ma
versus 4C: Angiotensin II-stimulated, Inflammation mediated by chemokine
and cytokine, Dopamine receptor, Endogenous cannabinoid, Endothelin,
GABA-B receptor, Heterotrimeric G-protein, Integrin, PI3 kinase, VEGF,
and Wnt. II) 4C112 versus 4C11+: 5HT receptor, Angiogenesis,
Inflammation mediated by chemokine and cytokine, EGFR, Endothelin, FGF,
Histamine receptor, Integrin, Interleukin, Oxidative stress, Oxytocin receptor,
PDGF, Ras, Thyrotropin-releasing hormone, Toll receptor, and VEGF.
(Figure 2B). Moreover, genes that significantly contributed to
stage-specific pathways were also identified. Thus, deregulation of
pathways Aminobutyrate degradation and Phenylethylamine degradation
characterized the transition from melan-a melanocytes to 4C pre-
malignant melanocyte lineage. Besides that, the pathways Blood
coagulation and General transcription by RNA polymerase I marked the
transition from 4C pre-malignant melanocytes to 4C112 non-
metastatic melanoma cell line. Furthermore, sixteen signaling
pathways marked the acquisition of a metastatic phenotype as
follows: 2 Arachidonoylglycerol biosynthesis, Adenine/hypoxanthine salvage,
Apoptosis, B cell activation, DNA replication, Fas, FGF, Fructose galactose
metabolism, N-acetylglucosamine metabolism, P53, P53 feedback loops 2,
Purine metabolism, Ras, Synaptic vesicle trafficking, T cell activation, and
Figure 1. Tumorigenicity and Metastatic Capabilities Were
Acquired by melan-a Melanocytes after Detachment/Re-adhe-
sion Cycles. (A) Tumorigenicity assay in vivo. Mice were subcutane-
ously injected with melan-a melanocyte lineage and its derived cell
lines 4C, 4C112 and 4C11+ (2.5x105 cells per mouse). Tumor volume
was measured during 100 days (n=5 animals for each group, P,0.01 by
One-Way ANOVA test for significance). (B) Metastasis capacity in vivo.
Lungs of mice were analyzed after tail vein injection of 4C112 and
4C11+ melanoma cell lines (2.5x105 cells per mouse). Melan-a and 4C
non-tumorigenic melanocyte lineages were used as negative controls.
Tumor multiplicity is indicated by the number of lung tumor nodules
formed by 4C11+ melanoma cell line (n= 5 animals for each group,
P,0.0001 by One-Way ANOVA test for significance). (C) Survival curves
of mice injected intravenously with 4C112 and 4C11+ melanoma cell
lines (2.5x105 cells per mouse) (n=5 animals for each group, P,0.0001
by Log-rank test for significance). Poor clinical outcomes were observed
for all animals injected with 4C11+ metastatic melanoma cell line.
doi:10.1371/journal.pone.0044800.g001
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Triacylglycerol metabolism (Figure 2B-2C). Finally, we investigated
whether the genes from different class-comparison experiments
shared one or more cellular pathways. As a result, we found
pathways commonly perturbed between the transitions from
melan-a melanocytes to 4C pre-malignant melanocytes and
4C112 non-metastatic to 4C11+ metastatic melanoma cells.
Therefore, we noted that genes from the pathways TGF-b, Notch,
Insulin/IGF pathway-PKB, Insulin/IGF pathway MAPKK/MAPK,
Cytoskeletal regulation by Rho GTPase, Cadherin signaling, and Alzheimer
disease-presenilin signaling were over-represented in 4C pre-malignant
melanocytes in relation to melan-a cells, and under-represented in
4C11+ metastatic melanoma cell line in relation to 4C112 non-
metastatic melanoma cells. Furthermore, we also observed
neuroendocrine pathways commonly down-regulated in the
transition from melan-a melanocytes to 4C pre-malignant
melanocytes, and up-regulated in the transition from 4C112
non-metastatic to 4C11+ metastatic melanoma cell lines, as
follows: 5HT degradation, Adrenaline/NOR biosynthesis, Cortocotropin-
releasing factor, Muscarinic acetylcholine receptor, Opioid and b-adrenergic
receptor as well. Interestingly, the transition from 4C pre-malignant
melanocytes to 4C112 non-metastatic melanoma cells was
marked by the over-representation of genes from the Histamine
synthesis-related pathway. Nonetheless, such pathway was over-
represented in the transition from 4C112 non-metastatic mela-
noma to 4C11+ metastatic melanoma cells. Therefore, we provide
evidence that stress-driven changes in the environment can impair
the neuroendocrine activity of the melanocytes in the initial stages
associated with malignant transformation of melanocytes. Togeth-
er, these results provide insights into the aetiology and pathogen-
esis of malignant melanomas by suggesting that early melanocytic
lesions would be useful to predict a functional phenotype
associated with metastasis (Figure 2B-2D). Importantly, pertur-
bations on the expression of genes associated with epigenetic
machinery were identified as molecular markers of tumor
progression in our melanoma model (Figure 2E) [11].
Demethylating Agent 5AzaCdR Differentially Modulated
Gene Expression at Specific Stages of Melanoma
Progression
Previously, we reported that the differential expression of
Dnmt1 and Dnmt3a at protein level were associated with melan-a
malignant transformation. Additionally, we demonstrated that the
treatment with 10 mM 5-aza-29-deoxycytidine (5AzaCdR) for
48 hours was able to inhibit the tumorigenicity capacity of the
4C11+ metastatic melanoma cell line in vivo [11]. Besides that, a
growing body of data has shown that epigenetic modifier drugs
can affect a number of tumor cell phenotypes, including the
proliferation of melanoma cells [18,19]. As the first step in
characterizing the global demethylation responses induced by
DNA hypomethylating agents, melan-a, 4C, 4C112 and 4C11+
cell lines were treated with 10 mM 5AzaCdR for 48 hours. The
establishment of this treatment condition for 5AzaCdR was
justified since we aimed to maximize demethylation efficiency and
to minimize drug toxicity as well. Cell toxicity and viability were
monitored by using a standard methyl thiazol tetrazolium assay
(MTT), as previously described [11]. Following treatment of cells,
there was a substantial decrease of genomic DNA methylation,
since all treated cells showed significant percent of demethylation
when compared with untreated cells. The decrease in global DNA
methylation was observed at the same extent in 4C pre-malignant
melanocytes, 4C112 non-metastatic, and 4C11+ metastatic
melanoma cells as well (Figure 3A). In order to identify candidate
genes targeted, either directly or indirectly, by aberrant DNA
methylation at specific stages of melanoma progression, a genome-
wide screening was performed in melan-a, 4C, 4C112 and 4C11+
cell lines after their treatment with 5AzaCdR at the time and
concentration indicated. The high-throughput Affymetrix micro-
array approach was used as a platform screening, as described
above. The experiments were carried out in two biological
replicates. Class-comparison experiments were performed, and
transcripts were selected as statistically significant by the pairwise
two-class SAM analysis (FDR and Q-values,0.05) by using 500
random permutations as follows: I) gene expression profile of the
parental melan-a melanocyte lineage versus its 5AzaCdR-treated
counterpart cell: 250 up-regulated genes upon 5AzaCdR treat-
ment; II) gene expression profile of 4C pre-malignant melanocyte
lineage versus its 5AzaCdR-treated counterpart cell: 81 up-
regulated genes upon 5AzaCdR treatment; III) gene expression
profile of 4C112 non-metastatic melanoma cell line versus its
5AzaCdR-treated counterpart cell: 569 up-regulated genes upon
5AzaCdR treatment; IV) gene expression profile of 4C11+
metastatic melanoma cell line versus its 5AzaCdR-treated
counterpart cell: 359 up-regulated genes upon 5AzaCdR treat-
ment (Figure S2, Tables S1–S4). To identify candidate tumor
suppressor genes whose expression could be modulated by
epigenetic agents in distinct phases of melan-a malignant
transformation, we performed genome-wide association studies
for melan-a versus 4C, 4C versus 4C112, and 4C112 versus
4C11+ cell lines as follows: I) intersection between genes found
significantly down-regulation in 4C pre-malignant melanocytes in
comparison to melan-a melanocyte lineage, and our list of over-
expressed genes upon 5AzaCdR treatment in 4C melanocytes; II)
intersection between genes found significantly down-regulation in
Table 1. An overview of chromosomal aberrations during melanoma progression.
Cell Line
Chromosome
Number
Centromere
Fragments Recurrent Structural Chromosomal Changes
melan-a* 54 21 None
4C* 51 31 T[8;14] {19}/T[14;8] {21}/T[15;X] {18}/F[8;6] {4}/Del[11] {18}
4C112 51 31 T[8;14] {13}/T[14;8] {14}/ T[7;X] {6}/T[15;X] {11}/F[8;6] {19}/Del[11] {16}
4C11+ 70 5 T[1;16] {19}/T[8;1] {20}/T[1;12] {10}/T[3;13] {19}/T[13;3] {15}/T[X;15] {15}/Rb[8.12]
{14}/Rb[12.12] {30}/Del[1] {18}/Del[11] {16}
The karyotype descriptions indicated by ’*’are derivatives from analyses previously performed by Silva et al [17].
The number of chromosomes and centromere fragments in the cell line panel are derivatives from the analyses of 20 metaphases per cell line examined.
The braces indicate how often each rearrangement was seen in 20 methaphases.
Del: deletion; F: fusion; Rb: Robertsonian fusion; T: translocation.
doi:10.1371/journal.pone.0044800.t001
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4C112 non-metastatic melanoma cell line in comparison to 4C
pre-malignant melanocyte lineage, and our list of over-expressed
genes upon 5AzaCdR treatment in 4C112 melanoma cell; III)
intersection between genes found significantly down-regulation in
4C11+ metastatic melanoma cell line in comparison to 4C112
non-metastatic melanoma cell, and our list of over-expressed genes
Figure 2. Pre-Malignant Melanocytes and Metastatic Melanomas Shared Deregulated Pathways. (A) Gene expression profiles of melan-
a, 4C, 4C11– and 4C11+ cell lines revealed differentially up- and down-regulated genes in the transitions associated with malignant transformation of
melan-a melanocytes (from melan-a to 4C, 4C to 4C112, and 4C112 to 4C11+ cells). Transcripts were selected as statistically significant by the
unpairwise two-class SAM analysis (FDR and Q-values,0.05). (B) PANTHER software was used to determine pathway profiles deregulated in the
course of melanoma progression. (C) Venn diagram pointed out pathways deregulated at specific stages of melan-a malignant transformation. (D)
Identification of pathways commonly over-represented in 4C pre-malignant melanocytes in relation to melan-a cells, and under-represented in 4C11+
metastatic melanoma cell line in relation to 4C112 non-metastatic melanoma cells. (E) Epigenetic signature as a candidate marker associated with
the transition from non-metastatic to metastatic phenotype. ma: immortalized, but non-tumorigenic, melan-a melanocyte lineage; 4C: pre-malignant
melanocyte lineage; 4C112: non-metastatic melanoma cell line, and 4C11+: metastatic melanoma cell line.
doi:10.1371/journal.pone.0044800.g002
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upon 5AzaCdR treatment in 4C11+ melanoma cell (Figure 2A,
Tables S1–S4). Finally, the resulting genes were plotted in
heatmaps (Pearson correlation metric distance; average linkage
algorithm) organized according to the sequential stages of melan-a
malignant transformation (Figure 3B–3D). In total, 11 genes
showed responsiveness to 5AzaCdR treatment at stage I
(Figure 3B), 9 genes at stage II (Figure 3C), and 136 genes at
stage III (Figure 3D) of melanoma progression. Three genes were
selected for further validation of gene expression (Xist, Hspb1 and
Serpine1) (Figure 3B–3D). These genes, except for Hspb1 [18],
were not previously reported to be modulated by 5AzaCdR
treatment in melanoma cells. Despite the fact that the genes Xist
and Hspb1 were found deregulated earlier in the process of
malignant transformation of melan-a melanocytes, studies have
shown they are likely to have distinct functional roles in the tumor
progression [20–22].
Candidate Markers for melan-a Malignant Transformation
In recent years, it became evident that HDAC inhibitors such as
Trichostatin A (TSA) in combination to DNA demethylation
agents such as 5AzaCdR are attractive epigenetic agents to
synergistically increase the expression of tumor silenced-genes in
cancer [13,23–25]. Along this line of evidence, the differential
expression of selected genes were validated using quantitative real-
time approach (RT-qPCR) in melan-a, 4C, 4C112 and 4C11+
cell lines previously exposed to three protocols based on epigenetic
drug therapy: 40 nM TSA for 16 hours, 10 mM 5AzaCdR for
48 hours, and 10 mM 5AzaCdR for 48 hours plus 40 nM TSA for
16 hours (Figure 4). The rationale for the establishment of these
treatment conditions for TSA and 5AzaCdR combined with TSA
was based on the same explanation as those for 5AzaCdR alone,
but also exploring, directly or indirectly, the acetylated state of
genes. Cytotoxicity and cell viability were monitored by MTT
assays, as previously described [11]. RT-qPCR revealed that the
expression of Xist was negative in all melan-a-derived cell lines
compared to melan-a melanocytes. The treatment of the 4C pre-
malignant melanocyte as well as 4C112 non-metastatic melano-
ma cell line with 5AzaCdR plus TSA resulted in the highest up-
regulation of Xist expression. On the other hand, we observed a
more robust up-regulation of Xist gene expression when 5AzaCdR
alone was given to 4C11+ metastatic melanoma cells. Further-
more, a slight decrease in the relative intensity of Xist gene
expression was noted when TSA alone was given to melan-a
melanocytes as well as 4C11+ metastatic melanoma cell line
(Figure 4A). The dynamic of Hspb1 gene expression was
characterized by a significant enrichment found at pre-malignant
and non-metastatic stages (4C melanocyte lineage and 4C112
melanoma cell line, respectively) in relation to melan-a melano-
cytes, followed by a progressive loss in Hspb1 expression in 4C11+
metastatic melanoma cell line when compared with 4C pre-
malignant melanocyte and 4C112 non-metastatic melanoma cell.
The treatment of the 4C112 non-metastatic melanoma cell line
with TSA resulted in no significant change of Hspb1 mRNA
expression. Despite this fact, the highest up-regulation of Hspb1
expression was induced by the combination of 5AzaCdR and TSA
(. 12 times increase). At metastatic stage (4C11+ melanoma cell
line), treatment with either TSA or 5AzaCdR was able to enhance
Hspb1 expression, but when TSA and 5AzaCdR were combined, a
slight increase in the relative intensity of Hspb1 gene expression
was noted above individual drugs. As a whole, there was no
significant change in Hspb1 expression at pre-malignant stage (4C
melanocyte lineage), except a slight increase when 5AzaCdR
treatment was done. At immortalized, but non-tumorigenic stage
(melan-a melanocytes), we observed a more robust up-regulation
of Hspb1 gene expression by 5AzaCdR and TSA combination
than by 5AzaCdR alone (Figure 4B). Serpine1 gene expression was
significantly higher in the initial phases of melanoma genesis (4C
pre-malignant melanocyte and 4C112 non-metastatic melanoma
cell line) than immortalized melanocyte lineage (melan-a). On the
other side, a progressive loss of Serpine1 expression was found in
4C11+ metastatic melanoma cell line when compared with 4C
pre-malignant melanocyte lineage and 4C112 non-metastatic
melanoma cells. Although Serpine1 expression was significantly
higher in melan-a melanocyte lineage treated with 5AzaCdR and
TSA, a meticulous dynamic in its expression was observed across
the therapeutic spectrum. The 4C pre-malignant melanocyte
lineage showed a progressive enhancement of Serpine1 gene
expression as follows: TSA alone (. 5), 5AzaCdR alone (. 9),
and 5AzaCdR plus TSA (. 14 times increase) treatment. These
results showed a synergistic effect of epigenetic agents to increase
the expression of Serpine1 gene at pre-malignant stage. There was
no significant difference in Serpine1 mRNA levels in previously
untreated 4C112 non-metastatic melanoma cell line relative to its
5AzaCdR+TSA-treated counterpart cell. When 4C112 melano-
ma cell was treated with TSA alone, the increase in Serpine1 gene
expression was higher than 5AzaCdR alone (at least 22 times
increase). Besides that, 4C11+ metastatic melanoma cell line
showed a striking enhancement of Serpine1 gene expression (. 93
fold enrichment) when TSA alone was given, indicating TSA as
the most effective epigenetic compound for Serpine1 up-regulation
at metastatic stage. Noteworthy, such enhancement of Serpine1 at
mRNA level returned close to basal level observed in previously
untreated 4C11+ metastatic melanoma cell line when 5AzaCdR
alone or in combination to TSA was given (. 10 and . 17 fold
enrichment, respectively) (Figure 4C). We also found a set of
differentially up-regulated genes in 4C11+ metastatic melanoma
cell line in relation to its 4C112 non-metastatic counterpart cell
(Figure 2A). Curiously, some of them displayed significantly up-
regulation upon 5AzaCdR treatment in 4C11+ melanoma cell
such as Fblim1 (Table S4), a cytoskeleton regulator that can
control integrin activation and cancer progression [26]. Along this
line, an additional transcript was validated by RT-qPCR as a
candidate oncogene aberrantly over-expressed in 4C11+ meta-
static melanoma cell line. As a result, we found a significant
enrichment in Fblim1 gene expression in 4C112 and 4C11+
melanoma cell lines when compared with melan-a melanocyte
lineage. The 4C112 non-metastatic melanoma cell line showed
no significant change in Fblim1 expression when treated with TSA
alone. On the other hand, approximately five times increase in
Fblim1 expression was observed after 5AzaCdR treatment, and
. 7.5 times increase when 5AzaCdR combined with TSA was
given. Besides that, the 4C11+ metastatic melanoma cell line
showed a progressive enhancement of Fblim1 gene expression as
follows: TSA alone (. 3.5), 5AzaCdR alone (. 5), and 5AzaCdR
plus TSA (. 6.5 times increase) treatment. The highest up-
regulation of Fblim1 expression was induced by the combination of
5AzaCdR and TSA in melan-a melanocytes. At pre-malignant
stage (4C melanocyte lineage) we observed no significant change in
Fblim1 expression when TSA treatment was done. On the other
side, when 5AzaCdR treatment was given alone or in combination
to TSA, a significant up-regulation of Fblim1 expression was found.
Therefore, the treatment with 5AzaCdR alone or in combination
to TSA showed a great potential to up-regulated Fblim1 gene in
cell lines with the lowest Fblim1 expression (melan-a and 4C
melanocytes) (Figure 4D). Despite the fact that RT-qPCR
approach was more sensitive than microarray-based gene expres-
sion studies, there was a good correlation between mRNA profiles
detected by microarrays and RT-qPCR techniques for the novel
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candidate markers implicated in malignant transformation of
melan-a melanocytes.
Demethylating Agent 5AzaCdR Combined with the
HDAC Inhibitor TSA Modulate Cell Morphology and Gene
Expression in Human Primary Melanocytes
To better follow up the steps of melanoma progression, we first
examined the effect of TSA, 5AzaCdR, and 5AzaCdR plus TSA
treatments on morphology of FM305 human primary melano-
cytes. The primary melanocytes exhibited the highest change on
cell morphology when treated with 5AzaCdR in combination to
TSA (Figure 5A). Based on this, we next investigated whether the
differentially expressed genes validated as candidate markers for
melan-a malignant transformation could respond to epigenetic
compounds in human specimens. To do this, HSPB1, SERPINE1
and FBLIM1 genes were further validated in two patient-derived
right supraclavicular lymph node metastases (Mel-2 and Mel-3 cell
lines) previously exposed to 10 mM 5AzaCdR for 48 hours
followed by 40 nM TSA for 16 hours. Interestingly, we observed
the same profile of drug responsiveness for FM305 human primary
melanocytes (Figure 5C-5E) and melan-a mouse melanocyte
Figure 4. Candidate Markers for melan-a Malignant Transformation. (A) Xist, (B) Hspb1, (C) Serpine1 and (D) Fblim1 genes were assessed for
relative quantification (RQ) in mouse cell lines across the melanoma progression spectrum (melan-a, 4C, 4C112 and 4C11+) non-treated (NT) or
previously treated with 40 nM TSA for 16 hours, 10 mM 5AzaCdR for 48 hours, and 10 mM 5AzaCdR for 48 hours plus 40 nM TSA for 16 hours. Relative
gene expression was calculated according to 2-DDCq method, using cellular Actb mRNA levels as endogenous reference control. Error bars in all cases
represent SEM and P values were based on Students’ t test or One-Way ANOVA test followed by the post-hoc Tukey. *P,0.05, **P,0.01, ***P,0.001.
ma: immortalized, but non-tumorigenic, melan-a melanocyte lineage; 4C: pre-malignant melanocyte lineage; 4C112: non-metastatic melanoma cell
line, and 4C11+: metastatic melanoma cell line. TSA: Trichostatin A; 5AzaCdR: 5-aza-29-deoxycytidine.
doi:10.1371/journal.pone.0044800.g004
Figure 3. Demethylating Agent 5-aza-29-deoxycytidine Differentially Modulated Gene Expression at Specific Stages of Melanoma
Progression. (A) The 4C pre-malignant melanocytes, 4C112 non-metastatic and 4C11+ metastatic melanoma cell lines displayed the same percent
of global genomic DNA demethylation upon 5AzaCdR treatment. (B-D) Genome-wide association studies of melan-a, 4C, 4C112 and 4C11+ cell lines
untreated and previously exposed to 5AzaCdR revealed re-expressed genes at a given transition associated with melan-a malignant transformation.
Heatmaps were generated by unsupervised hierarchical clustering using the Pearson correlation as metric distance and average-linkage as algorithm
as well. The saturation of either color (scale from green to red) reflects the magnitude of the difference on gene expression level. ma: immortalized,
but non-tumorigenic, melan-a melanocyte lineage; 4C: pre-malignant melanocyte lineage; 4C112: non-metastatic melanoma cell line, and 4C11+:
metastatic melanoma cell line. 5AzaCdR: 5-aza-29-deoxycytidine.
doi:10.1371/journal.pone.0044800.g003
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lineage (Figure 4B-4D) in relation to the expression of genes
HSPB1/Hspb1, SERPINE1/Serpine1, and FBLIM1/Fblim1. In spite
of this, only the SERPINE1/Serpine1 gene showed the same
treatment responsiveness when 5AzaCdR combined with TSA
was given to 4C11+ mouse metastatic melanoma cell line as well as
Mel-2 and Mel-3 human metastatic melanoma cells. The
treatment conditions for all human cells were the same as those
described for mouse cell lines, and cell viability was monitored by
the Trypan Blue assays (data not shown). Furthermore, we
investigated the differential expression of genes HSPB1, SERPINE1
and FBLIM1 in a panel of five patient-derived metastatic
melanoma cell lines in comparison to FM305 primary melano-
cytes. Based on the clinical staging criterion measured by the time
from post treatment of primary tumors to re-occurrence of the
diseases, we have distinguished two groups of metastases: M1
(Mel-2 and Mel-3: better prognosis), and M2 (Mel-11, Mel-14 and
Mel-33: worst prognosis). RT-qPCR approach revealed a unifying
profile of gene expression in which FBLIM1, HSPB1 and
SERPINE1 up-regulation significantly distinguishes less aggressive
metastases (Mel-2 and Mel-3) from those displaying more
aggressiveness (Mel-11 and Mel-14) (Figure 5C-5E). Curiously,
the expression profile exhibited for the genes HSPB1 and
SERPINE1 in Mel-2 and Mel-3 human metastases was noted for
mouse cell lines representing pre-malignant melanocytes and non-
metastatic melanoma cells (4C and 4C112 cell lines, respectively)
in comparison to melan-a melanocytes (Figure 4B-4C,
Figure 5C-5D). Additionally, we investigated by RT-PCR the
expression of XIST in two female patient-derived metastatic
melanoma cell lines with high degree of aggressiveness (Mel-11
and Mel-33). The positive correlation on expression of Xist/XIST
was seen for 4C11+ mouse metastatic melanoma cell line and Mel-
33 (inguinal lymph node metastasis), but not for Mel-11 (brain
metastasis) (Figure 4A, Figure 5B).
Treatment of Human Melanocytic Cells with Epigenetic
Compounds Modulate the Expression of Genes
Recognized by Affecting Melanocyte Biology and
Response to Cancer Therapy
As the first step in identifying genes implicated in melanocyte
biology, whose expression were deregulated in the progression of
melanomas, we performed a manual annotation of the 136 genes
significantly down-regulated in the transition from 4C112 to
4C11+, and up-regulated in 4C11+ metastatic melanoma cells
upon 5AzaCdR treatment. Two genes were selected for validation
of gene expression (NDRG2 and VDR) (Figure 3D) [27–30].
Moreover, we were also interested in identifying genes potentially
implicated in response to cancer therapy. Along this line, we
selected the gene NSD1 (Figure 3D) [31] as well as two additional
genes based on the literature searched for further validation (CTCF
and SRC) [32,33]. Therefore, the expression pattern of human
NDRG2, VDR, NSD1, CTCF and SRC genes in several human
metastatic melanoma cell lines in comparison to primary
melanocytes were analyzed at mRNA level by RT-qPCR
methodology. The highest expression level of NDRG2 gene was
found in the brain (Mel-11), axillary lymph node (Mel-14), and
inguinal lymph node (Mel-33) metastases. On the other hand,
NDRG2 mRNA was nearly undetectable in the two right
supraclavicular lymph node metastases derivatives from the same
patient before and after the re-occurrence of the disease (Mel-2
and Mel-3 cell lines, respectively). Interestingly, when 5AzaCdR
treatment was given in combination to TSA, a significant up-
regulation of NDRG2 expression was found in Mel-2 metastatic
melanoma cells (Figure 6A). VDR gene expression was highly
positive in the metastases examined, except for Mel-33 cell line,
which was established from inguinal lymph node metastasis. A
slight decrease on VDR gene expression was observed when
5AzaCdR plus TSA treatment was given to Mel-2 and Mel-3
melanoma cells (Figure 6B). The significant up-regulation of
human NSD1 gene was found in all metastases evaluated, except
Mel-2, in comparison to primary melanocytes. The treatment
based on 5AzaCdR plus TSA caused a slight decrease on NSD1
gene expression in Mel-2 melanoma cells (Figure 6C). An
enhancement of CTCF gene expression was specifically found in
the aggressive metastases examined (Mel-11, Mel-14 and Mel-33)
in comparison to primary melanocytes. Mel-3 melanoma cells
showed a reduced expression on CTCF gene upon 5AzaCdR
combined with TSA treatment (Figure 6D). The SRC gene
expression was higher in the more aggressive metastases (Mel-14
and Mel-33) when compared to those presenting less aggressive-
ness (Mel-2 and Mel-3). Interestingly, the expression of SRC gene
had undergone down- and up-regulation, respectively, when Mel-
2 and Mel-3 melanoma cells were treated with 5AzaCdR
combined with TSA (Figure 6E). All genes evaluated had
undergone up-regulation in FM305 primary melanocytes upon
5AzaCdR+TSA treatment (Figure 6A-6E).
Hierarchical Clustering and Network Analyses Revealed
Novel Gene Interactions in Melanoma Progression
In an effort to elucidate the possible usefulness of the novel gene
expression signature as a marker of melanoma progression, we
performed an unsupervised hierarchical clustering (HCL) analysis
by grouping the five human metastatic melanoma cell lines
examined according to their patterns of gene expression (Pearson
correlation metric distance; average linkage algorithm). To do this,
mRNA levels of HSPB1, SERPINE1, FBLIM1, NDRG2, VDR,
NSD1, CTCF and SRC were measured after RT-qPCR approach
by using the 2-DDCq method, and plotted in a heatmap. Notably,
unsupervised HCL of patient-derived metastatic melanoma cell
lines was able to cluster samples into their theoretical cell type
branches (Figure 7A). Finally, Relevance Networks were gener-
ated allowing us to find, by an additional technique, some strong
gene regulatory relationships as candidate markers in advanced
melanomas. In such methodology, each pair of genes related by a
correlation coefficient larger than a minimum threshold and
smaller than a maximum threshold is connected by a line. Links
colored in red represent genes that are positively correlated while
links colored in blue represent genes negatively correlated. To
illustrate some findings, the relationships between pairs of genes
NDRG2/NSD1, VDR/NSD1, SRC/NSD1 as well as CTCF/
SERPINE1 were deregulated in four of five metastases examined.
Additionally, interactions between pairs of genes HSPB1/SER-
PINE1 as well as FBLIM1/SERPINE1 were found in three of five
metastases evaluated. These results highlight the potential
usefulness of the novel gene expression signature as a marker in
melanoma progression (Figure 7B).
Discussion
Up to date, classical chemotherapy as well as discovered
biomarkers have not been significant successful neither to
diagnosis melanomas or to benefit patients, with rare exceptions,
since only the gene CTLA4 and V600E mutational status of BRAF
gene have been recognized as bona fide targets to treat metastatic
disease [34,35].
In this study, we used a mouse model of melanoma progression
in which the non-tumorigenic melan-a melanocyte lineage was
submitted from anchorage-dependent to anchorage-independent
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Figure 5. Epigenetic Flexibility in Human Specimens. (A) Changes on cell morphology of human primary melanocytes after their exposure to
epigenetic modifier drugs, specially the combined therapy between 5AzaCdR and TSA. (B) Differential expression of XIST gene between two female
patient-derived metastatic melanoma cell lines. (C-E) Expression of genes HSPB1, SERPINE1 and FBLIM1 was modulated in response to epigenetic
compounds in human primary melanocytes and metastatic melanoma cells. Differential expression in a panel of five early-passage patient-derived
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culture conditions [15]. We reported that melan-a melanocytes
acquired features of aggressive melanoma cells after sequential
detachment/re-adhesion cycles. This aggressive phenotype was
characterized by a biological relationship between the complex
karyotype with Robertsonian fusions and metastatic capacity [16]
of 4C11+ melanoma cells in vivo (Figure 1B-1C, Table 1,
Figure S1).
Genome-wide screening of melan-a, 4C, 4C112 and 4C11+
cell lines revealed a large set of differentially up- and down-
regulated genes in the consecutive transitions implicated in melan-
a malignant transformation (from non-tumorigenic to metastatic
stage) (Figure 2A). It is well known that mammalian development
and cell type determination result from the tightly controlled
regulatory mechanisms between signaling pathways and transcrip-
tion factors in progenitor cells as well as environmental influences.
Interestingly, we showed that the conversion from melan-a
melanocytes to 4C pre-malignant melanocytes involved the
down-regulation of neuroendocrine pathways [36,37], providing
evidence that stress-driven changes in the environment can impair
the neuroendocrine activity of the melanocytes in the initial stages
of melan-a tumorigenic conversion. Additionally, we showed that
the conversion from 4C pre-malignant melanocytes to 4C11+
metastatic melanoma cells involved, among others, the down-
regulation on the expression of melanocyte stem cell-related
signaling pathways, such as TGF-b [38] and Notch [39]
(Figure 2B, 2D). This finding is in agreement with the data
reported earlier that melan-a melanocytes and 4C11+ metastatic
melanoma cells display an epithelial morphology, whereas 4C pre-
malignant melanocytes and 4C112 non-metastatic melanoma
cells exhibit a mesenchymal morphology with enhanced expres-
sion of the gene Chd1, and the presence of the repressive histone
mark H3K27 trimethylation plus the active mark H3K4
trimethylation [11]. Taken together, these findings would indicate
a less differentiated chromatin state. In terms of human cancer
biology, the stem cell chromatin state may enhance the likelihood
for DNA hypermethylation on tumor suppressor-coding genes
[40]. Based on the shared genetic background of the cells as well as
commonly perturbed pathways over-represented in 4C pre-
malignant melanocytes in relation to melan-a cells, and under-
represented in 4C11+ metastatic melanoma in relation to 4C112
non-metastatic melanoma cells (Figure 2D), our rationale was
that epigenetic reprogramming on gene expression occurring
earlier in melan-a malignant transformation would be useful to
predict a phenotype associated with metastasis.
Using genome-wide expression arrays we identified patterns of
gene expression following 5-aza-29-deoxycytidine (5AzaCdR)
exposure. Genome-wide association studies between untreated
cell lines and their 5AzaCdR-treated counterpart cells allowed us
to identify candidate down-regulated genes whose expression
could be modulated, directly or indirectly, by 5AzaCdR treatment
at specific stages of melanoma progression (Figure 3B-3D). A
gene expression signature was discovered and validated by RT-
qPCR in melan-a, 4C, 4C112 and 4C11+ mouse cell lines
(Figure 4A-4C). Moreover, candidate metastasis-related bio-
markers were validated in early-passage cultures of patient-derived
metastatic melanoma cell lines as well as primary melanocytes
untreated and/or previously treated with 5AzaCdR in combina-
tion to the HDAC inhibitor Trichostatin A (TSA) (Figure 5B-5E,
Figure 6).
A signature comprised by the genes Xist/XIST, Hspb1/HSPB1,
Serpine1/SERPINE1, Fblim1/FBLIM1, CTCF, NDRG2, NSD1, SRC
and VDR was selected for further validation by RT-qPCR
approach. XIST (X inactive-specific transcript) is the master
regulator of X-chromosome inactivation to equalize gene products
between male and female mammals, by inactivating one of the X-
chromosomes during the early embryonic development in females
(Lyon hypothesis, 1962) [41]. Apart from this, DNA copy number
changes of XIST gene was reported in colorectal carcinomas [22].
The positive correlation between HSPB1 (heat shock 27 KDa
protein 1) and SERPINE1 (serpin peptidase inhibitor, clade E,
member 1) overexpression induced reversal of the invasive and
metastatic phenotype of melanoma cells in vitro [20,21]. The
positive correlation between FBLIM1 (filamin binding LIM
protein 1) and SRC (v-src sarcoma viral oncogene homolog
[avian]) overexpression resulted in anoikis resistance contributing to
tumorigenicity of established carcinoma cells [42]. Additionally,
SRC activation was implicated with primary resistance to
PLX4032 in patient-derived melanoma cells [33]. The protein
encoded by the CTCF (CCCTC-binding factor) gene contributes
to the organization of DNA into loops of transcriptionally
repressive heterochromatin or into active euchromatin, which
facilitates blocks or which connects distal enhancers and proximal
promoters [12]. In terms of response to cancer therapy, the
insulator protein CTCF mediated the down-regulation of telome-
rase in response to sulforaphane exposure, a compound that has
histone deacetylase inhibition activity, in human breast cancer
cells [32]. NSD1 (nuclear receptor binding SET domain protein 1)
gene silencing was associated with tamoxifen resistance in breast
tumors [31]. The decrease on the expression of VDR (vitamin D
receptor) gene was linked to progression of pigmented skin lesions
as well as shorter patients’ melanoma overall survival [30]. Finally,
down-regulation of the NDRG2 (NDRG family member 2) gene
was reported to inhibit the metastatic potential of melanoma cells
in vitro and in vivo [27,28].
Even though much has been discussed about the discrepancies
between mouse and human mechanisms of carcinogenesis,
network analysis showed, for example, the interaction between
pairs of genes HSPB1/SERPINE1 as well as FBLIM1/SERPINE1
in some of the human metastases examined (Figure 7B).
Moreover, up-regulation on the expression of Serpine1/SERPINE1
gene upon 5AzaCdR plus TSA treatment was found in 4C11+
mouse metastatic melanoma cells as well as Mel-2 and Mel-3
patient-derived metastases (Figure 4C, Figure 5D). In addition,
melan-a mouse melanocyte lineage and FM305 human primary
melanocytes shared the up-regulation on the expression of HSPB1,
SERPINE1 and FBLIM1 genes when 5AzaCdR associated with
TSA was given (Figure 4B-4D, Figure 5C-5E).
Hierarchical clustering of human metastatic melanoma cells was
able to group samples into their theoretical cell type branches
(Figure 7A). Despite the fact that it could be a marker of
molecular heterogeneity, network analysis pointed out gene
interactions commonly perturbed among the metastases evaluated
such as NDRG2/NSD1, VDR/NSD1, SRC/NSD1, CTCF/SER-
PINE1, HSPB1/SERPINE1 and FBLIM1/SERPINE1 (Figure 7B).
metastases was also determined by RT-qPCR. Relative gene expression was calculated according to 2-DDCq method, using cellular ACTB mRNA levels
as endogenous reference control. Error bars in all cases represent SEM and P values were based on Students’ t test or One-Way ANOVA test followed
by the post-hoc Tukey. *P,0.05, **P,0.01, ***P,0.001. FM305: human primary melanocytes from neonatal foreskin; Mel-2: right supraclavicular
lymph node metastasis; Mel-3: counterpart of Mel-2 after the re-occurrence of the disease; Mel-11: brain metastasis; Mel-14: axillary lymph node
metastasis, and Mel-33: inguinal lymph node metastasis. TSA: Trichostatin A; 5AzaCdR: 5-aza-29-deoxycytidine.
doi:10.1371/journal.pone.0044800.g005
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Interestingly, deregulation on the expression of epigenetic
machinery components such as CTCF and the NSD1 histone
methyltransferase-coding genes was noted in human metastases
(Figure 6C-6D, Figure 7). An epigenetic signature was also
found deregulated in 4C11+ mouse metastatic melanoma in
relation to 4C112 non-metastatic melanoma cells (Figure 2E).
Together, these results could suggest the involvement of epigenetic
abnormalities in melanoma progression. However, the regulatory
mechanisms have yet to be determined. To illustrate some
potential contribution of our findings in the context of melanoma
progression, the interaction between the pair of genes CTCF/
SERPINE1 (Figure 7B) might impair P53-mediated senescence in
melanomas even in the absence of direct genetic or epigenetic
lesions. It is justified since SERPINE1 gene is a critical downstream
target of P53 gene in the induction of replicative senescence [43].
Additionally, the P53 gene promoter was reported to be regulated
by the CTCF transcription factor in transformed cell lines [44]. In
fact, evidence is emerging that epigenetic changes might play a
significant role in tumor cell plasticity and the metastatic
phenotype of melanoma cells [10].
Notably, FM305 human primary melanocytes were able to alter
their morphology (Figure 5A) and gene expression (Figure 5C-
5E, Figure 6) in response to 5AzaCdR plus TSA exposure. To
our knowledge, this is the first report suggesting an epigenetic
flexibility in normal primary melanocytes in response to alterations
in their environment promoted by the exposure to epigenetic
modifier drugs. If this ‘epigenetic flexibility’ can translate in
plasticity and changes on cellular behavior will need to be carefully
evaluated in the future.
Finally, accumulating evidences implicate the molecular cou-
pling of differentiation program patterns and melanoma stem cells
in the establishment of drug tolerance and response to melanoma
therapy. In addition, resistance to apoptosis and the chromatin
state of genes act as hallmarks of drug resistance [1,45–48]. To
identify mechanisms underlying successful melanoma therapy,
some points need to be carefully discussed: i. This study was
performed by using a mouse model of melanoma progression in
which sequential detachment/re-adhesion cycles of non-tumori-
genic melan-a melanocyte lineage caused cells to adopt 3D cluster
morphology, a progressive anoikis-resistance phenotype [15,49]
and the acquisition of malignant phenotype and a metastatic
behavior of 4C11+ melanoma cell line as well (Figure 1); ii.
Melanoma stem cell markers are dynamically regulated in each
transition associated with melan-a tumorigenic conversion (Fig-
ure S3). Noteworthy, Cheli and coworkers (2011) reported that
the inhibition of microphthalmia-associated transcription factor
(MITF), the master regulator of melanocyte lineage commitment
and differentiation, increased the tumorigenic potential of human
melanoma cells whereas up-regulated stem cell markers and
enhanced the number of melanoma-initiating cells in human
melanoma spheroids. Thus, authors concluded that MITF acts as
the key molecular switch between human melanoma initiating
cells and their differentiated progeny [48]. Melan-a, 4C, 4C112
and 4C11+ cell lines vary in their differentiation program patterns
(Figure S3; Camila Ferreira de Souza, manuscript in prepara-
tion). Despite this fact, it is so premature to conclude that the
spheroid cells found after the anchorage blockage of 4C pre-
malignant melanocytes are cancer stem cells. Further studies need
to be carefully conducted to address this issue. Such characteriza-
tion might carry important clinical implications as cancer stem
cells show increased resistance to chemotherapy; iii. The
chromatin modifying enzymes such as increased JARID1A and/
or increased histone deacetylases (HDACs) can reversibly mediate
the acquisition of a drug tolerant state in melanomas [46].
Importantly, we previously reported that many histone marks
differ among melan-a, 4C, 4C112 and 4C11+ cell lines, which
could be associated with aberrant gene expression [11] (and data
not shown). The notion that epigenetics is associated with
widespread gene expression changes in cancer is not new. Some
studies have pointed out that transcriptional factors, epigenetic
complexes and pluripotency markers cooperate to modulate the
expression of XIST gene. In addition, the presence of histone
acetyltransferases (HATs) are related to the expression of VDR
gene [50–53]. However, the relationship between them at a given
stage of disease appears to be complex and certainly merits a
careful exploration. Curiously, Do and coworkers (2008) showed
an enhancement in Dnmt3a RNA levels after TSA treatment in
female neurosphere cells suggesting that Dnmt3a gene expression is
controlled by histone modification. Importantly, depletion of
Dnmt3a mRNA was sufficient to inhibit the de novo methylation of
the Xist region after TSA treatment, although Xist RNA level was
slightly reduced. Together, these findings indicate that Dnmt3a
has a direct effect on Xist methylation acting as a negative
regulator of Xist gene as well [51]. We previously showed that the
expression of Dnmt1 and Dnmt3a at protein level was detected in
melan-a melanocytes. Besides that, the up-regulation of Dnmt3a
protein was only found for 4C11+ metastatic melanoma cell line
[11]. Interestingly, a slight decrease in the relative intensity of Xist
gene expression was noted when TSA was only given to melan-a
melanocytes and 4C11+ metastatic cells (Figure 4A). Thus, it is
reasonable to hypothesize that no one molecular mechanism
accounts for the properties of DNA methyltransferase and histone
deacetylase inhibitors, even at a specific gene locus. It could
explain, for example, others apparent opposite results, such as: i)
The treatment of the 4C pre-malignant melanocytes and 4C112
non-metastatic melanoma cell line with 5AzaCdR plus TSA
resulted in the highest up-regulation of Xist expression whereas a
more robust up-regulation of Xist gene expression in 4C11+
metastatic melanoma cell line was observed when 5AzaCdR alone
was given (Figure 4A); ii) The treatment of melan-a melanocytes
as well as 4C112 non-metastatic and 4C11+ metastatic melanoma
cell lines with 5AzaCdR in combination to TSA resulted in the
highest up-regulation of Hspb1 gene expression whereas no
significant change was observed at pre-malignant stage (4C
melanocyte lineage) except a slight increase when 5AzaCdR was
done (Figure 4B); iii) VDR gene expression was up-regulated in
FM305 primary melanocytes after combined 5AzaCdR and TSA
treatment whereas a slight decrease on VDR gene expression was
observed when the combinatorial treatment protocol was given to
Mel-2 and Mel-3 patient-derived metastatic melanoma cells
Figure 6. Epigenetic Drugs Modulated the Expression of Genes Recognized by Affecting Melanocyte Biology and Response to
Therapy. Expression of genes recognized by affecting (A-B) melanocyte biology, and (C-E) response to cancer therapy was deregulated in a panel of
five patient-derived metastatic melanoma cell lines in comparison to FM305 primary melanocytes, as assessed by RT-qPCR approach. (A-E) Epigenetic
compounds 5AzaCdR and TSA modulated the expression of genes NDRG2, VDR, NSD1, CTCF and SRC in normal melanocytes and metastatic
melanoma cells. Relative gene expression and Statistics were calculated as described in figure 5. FM305: human primary melanocytes from neonatal
foreskin; Mel-2: right supraclavicular lymph node metastasis; Mel-3: counterpart of Mel-2 after the re-occurrence of the disease; Mel-11: brain
metastasis; Mel-14: axillary lymph node metastasis, and Mel-33: inguinal lymph node metastasis. TSA: Trichostatin A; 5AzaCdR: 5-aza-29-deoxycytidine.
doi:10.1371/journal.pone.0044800.g006
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(Figure 6B). Integrating the regulatory information can support
positive or negative control of gene expression through synergism
and antagonism. Therefore, a major effort needs to be done to find
multiple regulatory signals, including epigenetic complexes,
differentially deregulated at several phases of melanoma progres-
sion. It could help find drugs that preferentially target cancer cells
by exploring the effects of 5AzaCdR and/or TSA treatment and
molecular heterogeneity in melanoma prevention.
To summing up, the current study demonstrates the utility of
our murine melanoma progression model to successfully identify
Figure 7. Hierarchical Clustering and Network Analyses Revealed Novel Gene Interactions in Melanoma Progression. (A) Heatmap of
five patient-derived metastatic melanoma cell lines. Metastases of human melanoma cell lines were clustered according to the expression profiles of
genes CTCF, FBLIM1, HSPB1, NDRG2, NSD1, SERPINE1, SRC and VDR. Heatmaps were generated by unsupervised hierarchical clustering using the
Pearson correlation as metric distance and average-linkage as algorithm as well. The saturation of either color (scale from green to red) reflects the
magnitude of the difference on gene expression level. (B) Despite the molecular heterogenety observed in melanoma cells, relevance networks
pointed out gene interactions commonly observed among the metastases examined, such as NDRG2/NSD1, VDR/NSD1, SRC/NSD1, CTCF/SERPINE1,
HSPB1/SERPINE1 and FBLIM1/SERPINE1. FM305: human primary melanocytes from neonatal foreskin; Mel-2: right supraclavicular lymph node
metastasis; Mel-3: counterpart of Mel-2 after the re-occurrence of the disease; Mel-11: brain metastasis; Mel-14: axillary lymph node metastasis, and
Mel-33: inguinal lymph node metastasis.
doi:10.1371/journal.pone.0044800.g007
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candidate biomarkers commonly perturbed in metastases. Fur-
thermore, it provides a platform for testing new agents in
combination therapies. Finally, the molecular markers deregulated
earlier in melanoma development should be validated in the future
in a large cohort of human specimens as a prognostic signature.
Materials and Methods
Model of Study
This work was done using an in vitro mouse melanoma model in
which the deregulation of cellular adhesion configured the
carcinogenic stimulus to melan-a (ma) melanocyte lineage. This
experimental model developed by our research group was
previously described [14,15]. It does not use physical, chemical
or environmental carcinogens or genetic manipulations, and can
easily be reproduced to study mechanisms of melanoma genesis in
a spectrum of distinct stages of tumor progression [15].
Melan-a, that is the first known established lineage of non-
tumorigenic mouse melanocytes, is a spontaneous immortal line of
pigmented melanocytes derived from normal epidermal melano-
blasts from embryos of inbred C57BL mice. Melan-a cells grow in
adherent condition and require 12-O-tetradecanoyl phorbol 13-
acetate (PMA) to grow [14]. Recently, our group has showed no
structural chromosomal abnormalities in melan-a cell line based
on karyotype analysis [17]. Thus, melan-a melanocytes provide an
excellent parallel non-tumorigenic lineage for studies of the
molecular basis of melanoma pathophysiology.
Shortly, four sequential anchorage blockade cycles of melan-a
melanocytes for 96 hours culminate with the establishment of the
melan-a derived subline corresponding to a non-tumorigenic, but
pre-malignant melanocyte lineage, which was called 4C. Apart
from this intermediate phenotype associated with melanomas,
distinct melanoma cell lines (4C112 and 4C11+, among others)
were established by limiting dilution of spheroids found after a new
anchorage blockade cycle of the 4C pre-malignant melanocyte
lineage. To perform repetitive deadhesion cycles, melan-a
melanocytes were plated at 1% agarose-coated plates, as
previously described [15]. We have characterized the 4C as a
pre-malignant melanocyte lineage since it presents a higher anoikis
resistance [49] and an aberrant differentiation program (Camila
Ferreira de Souza, manuscript in preparation) relative to its
parental melan-a cell line. Therefore, we are using a time-
dependent model of melanoma progression that was developed at
five different time-points to carefully analyze the molecular basis of
the tumorigenic conversion of melan-a melanocytes subjected to a
sustained stress condition, which was promoted by consecutive
detachment/re-adhesion cycles.
Cell Culture
Mouse melan-a melanocyte lineage was established by Prof.
Dorothy C. Bennett (Division of Biomedical Sciences, St.
George’s, University of London, UK) [14] and kindly provided
by Prof. Michel Rabinovitch (Departamento de Parasitologia,
Universidade Federal de Sa˜o Paulo, Brazil). Melan-a melanocytes
were grown in RPMI 1640 pH 6.9 medium (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS; Gibco BRL,
Grand Island, NY), 200 nM PMA (Sigma-Aldrich, Saint Louis,
MO) and antibiotics (Gibco) at 37uC with 5% CO2 in air. Cell
sublines derivatives from melan-a melanocytes after sequential
detachment/re-adhesion cycles (4C, 4C112 and 4C11+) were
grown under the same condition as the parental melan-a
melanocyte lineage, except for PMA, since they lost the
requirement of this factor to grow.
Human primary melanocytes from neonatal foreskin were
isolated after informed consent signed by patients according to the
Ethics Committee from Hospital Universita´rio (HU-USP, CEP
943/09) and kindly provided by Prof. Silvya S. Maria-Engler
(Departamento de Ana´lises Clı´nicas e Toxicolo´gicas, Universidade
de Sa˜o Paulo, Brazil). These cells were maintained in basal
medium for melanocytes 254CF supplemented with Human
Melanocyte Growth Supplement (HMGS) and 0.2 mM calcium
chloride (Gibco). Five short-term cultures of human melanoma cell
lines representing lymph node and systemic metastases (Mel-2,
Mel-3, Mel-11, Mel-14 and Mel-33) were patient-derived and
maintained in RPMI 1640 pH 7.2 medium (Gibco) supplemented
with 15% FBS (Gibco BRL), 2 mM L-glutamine, 1 mM sodium
pyruvate and antibiotics (Gibco). These cell lines, freshly derived
from surgery after informed consent signed by patients according
to human subjects’ research protocol approved by the Ethics
Committee of the Fundac¸a˜o Antoˆnio Prudente, Hospital A.C.
Camargo (CEP 096/98, 31/03/98), were a kindly gift from Dr.
De´bora Castanheira Pereira da Silva (Hospital A.C. Camargo).
Mice Studies
All in vivo studies were carried out in accordance with the
protocol approved by the Institutional Animal Care and Ethics
Committee of the Universidade Federal de Sa˜o Paulo (CEP 1509/
07 and 0389/09 from P.X. and C.F.S., respectively). Female
syngeneic C57Bl/6 mice were obtained at 6-8 weeks of age from
Biote´rio Central (Universidade Federal de Sa˜o Paulo, Brazil).
Animals were maintained on a 12 hours light/dark cycle and were
given free access to food in accordance to the International
Guiding Principles for Biomedical Research Involving Animals
(CIOMS; Genebra, 1985).
Melan-a, 4C, 4C112 and 4C11+ cell lines were harvested after
trypsin treatment of subconfluent monolayers, counted and
suspended in phosphate-buffered saline (PBS). To perform the in
vivo tumorigenesis assay, 2.5x105 4C112 and 4C11+ melanoma
cells per mouse were inoculated subcutaneously. Animals were
checked daily to monitor the presence of palpable tumors during
100 days. The growth tumor curves were determined by
measuring the tumor volume (mm3) as follows: d26D/2, in which
d corresponds to the smallest tumor diameter and D to the largest
one. To perform the in vivo experimental metastasis assay, 2.5x105
4C112 and 4C11+ melanoma cells per mouse were inoculated
intravenously into lateral tail vein. Mice were sacrificed, lungs
were surgically excised, and tumor multiplicities were evaluated by
measuring the presence and the number of metastatic pulmonary
foci. In both experiments, non-tumorigenic melan-a and 4C
melanocyte lineages were used as negative controls. Each
experimental group consisted of five animals. Statistical signifi-
cance (P,0.05) was determined using One-way ANOVA test.
Mice survival curves after intravenously inoculation of 4C112 and
4C11+ melanoma cells were calculated by the Kaplan-Meier
method, with the statistical significance (P,0.05) evaluated by the
Log-rank test. All statistics were carried out using GraphPad Prism
software version 5 for Windows (GraphPad, San Diego, CA).
Spectral Karyotyping Analysis (SKY)
In order to investigate structural chromosomal abnormalities
and rearrangements as indicators of karyotype evolution in
melanomas, SKY was performed using the ASI (Applied Spectral
Imaging, Vista, CA) kit for mice. Chromosome preparations were
hybridized and stained in accordance to manufacturer’s instruc-
tions. Imaging of the signals was carried out using the Spectra
Cube (ASI) system mounted on an Axioplan 2 microscope (Carl
Zeiss) with a 63x/1.4 oil objective and the Case Data Manager 4.0
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software (ASI). The chromosomes were counterstained with 4,6-
diamino-2-phenylindole (DAPI) in an anti-fade solution (ASI).
Twenty metaphases were evaluated per cell line examined.
Statistical significance (P,0.05) was calculated by the Kruskal-
Wallis test followed by the post-hoc Dunn’s. All statistics were
carried out using GraphPad Prism software version 4 for Windows
(GraphPad).
Treatment with Epigenetic Chemical Inhibitors
To analyze the DNA demethylation effects induced by 5-aza-29-
deoxycytidine (5AzaCdR; Calbiochem, Merck, Darmstadt, Ger-
many) on a genome-wide scale and in specific genes, mouse cell
lines (melan-a, 4C, 4C112 and 4C11+) in log phase were
incubated in medium supplemented with 10 mM of the chemical
compound for 48 hours. To analyze the histone deacetylase effects
induced by Trichostatin A (TSA; Calbiochem) on gene-specific
expression, mouse cell lines were incubated in medium supple-
mented with 40 nM of the chemical compound for 16 hours.
Finally, to analyze the synergistic effects between 5AzaCdR and
TSA on gene-specific expression, mouse and human cell lines were
incubated in medium supplemented with the both compounds, at
the concentrations and time indicated. In all of them, inhibitor-
treated cell lines were compared against their control cell
counterparts which were cultured in a paired way but in
inhibitor(s)-free culture medium. These treatment conditions do
not significantly induce cell toxicity since they were not able to
impair cell proliferation, as previously determined by us after
performing methyl thiazol tetrazolium (MTT) assays [11]. In
addition, Trypan Blue stain 0.4% was used to monitor cell viability
in a Countess Automated Cell Counter (Invitrogen, Carlsbad,
CA).
Digestion of Genomic DNA with MspI and HpaII
To evaluate the relative amount of global DNA methylation,
2 mg of genomic DNA extracted from melan-a, 4C, 4C112 and
4C11+ monolayers, as well as their 5AzaCdR-treated counterpart
cells, were digested or not with 2 mL of enzymes MspI or HpaII in
separeted reactions (Fast Digest, Fermentas, MD). The DNA was
digested for 16 hours at 37uC. Afterwards, 1 mL of each enzyme
was added, and the reactions were maintained for 1 hour at 37uC.
Then, samples were resolved onto 0.8% agarose gel electropho-
resis. The intensity of the bands corresponding to intact genomic
DNA, genomic DNA digested with MspI, and genomic DNA
digested with HpaII in each sample was determined using the
ImageJ software. Percentage of methylation was measured as
follows: relative global DNA methylation content = (HpaII-MspI)
6100/ genomic DNA. Percentage of demethylation was calculat-
ed as follows: 100-percentage of methylation.
RNA Extraction and Microarray-Based Gene Expression
Studies
Mouse cell lines (melan-a, 4C, 4C112 and 4C11+) were grown
and treated as previously described. For DNA demethylation and
high-throughput microarray-based gene expression studies, cells
were harvested by trypsinization at 48 hours. Total cell RNA
which was extracted from 5AzaCdR-treated and control cell
monolayers using TRIzol reagent (Invitrogen), was purified using
RNEasy MinElute Cleanup spin columns (QIAGEN, Dusseldorf,
Germany), according to manufacturer’s instructions. Only RNA
samples with an absorbance A260/A280 nm ratio greater than 2.0
were used for microarray hybridization. Briefly, 2 mg from total
RNA were amplified by an in vitro transcription reaction and
biotin-labeled. 39-IVT Expression Arrays (GeneChip Mouse
Genome 430_2.0, format 49; Affymetrix Inc., Santa Clara, CA)
which were hybridized under standard conditions for 16 hours at
45uC and 60 rpm, were washed, stained with streptavidin-
phycoerythrin and scanned using an Affymetrix GeneChip
Scanner 3000 7G. Gene expression experiments using Mouse
430_2.0 Arrays were done following the Affymetrix Expression
Analysis Technical Manual. Hybridization reactions and scanning
were carried out at Associac¸a˜o Fundo de Incentivo a` Psicofarma-
cologia (AFIP, Brazil).
Microarray and Pathway Analyses
In the chosen arrays, there are 45,101 probe sets which are
designed to investigate approximately 34,000 mouse transcripts.
We used GCOS software version 1.4 (Affymetrix) to extract
expression values (raw array data) generated from Mouse 430_2.0
Array experiments, according to standard procedures by Affyme-
trix Systems. To identify differentially expressed genes in the
transitions from melan-a to 4C, 4C to 4C112, and 4C112 to
4C11+ cell lines, class-comparison experiments were performed,
and transcripts were selected as statistically significant by the two-
class unpaired SAM analysis with 700 random permutations
(FDR,0.05). The experiments were carried out in three biological
replicates. To estimate differences on gene responsiveness upon
5AzaCdR treatment in each cell line, 5AzaCdR-treated cells were
compared against their previously untreated counterpart cells.
Transcripts were selected as statistically significant by the two-class
paired SAM analysis with 500 random permutations (FDR,0.05).
The experiments were carried out in two biological replicates.
The raw array data (.CEL files) were first quantile normalized
with background correction using RMAExpress version 1.0.5
[54]. Next, the normalized expression values (log2 scale) were
filtered due to strict quality criteria. Filtering and statistics were
carried out using MultiExperiment Viewer (MeV) version 4.6
from The Institute of Genomic Research (TIGR; Rockville, MD)
[55]. This filtering reduces the number of probes to 36,080 but
increases the consistency of the measurements as shown by the
removal of genes that did not vary much in expression over the
conditions of the experiment. This variance filter was performed
after quality control filters, such as lower and percentage cutoffs,
were imposed. This methodology insures that the genes that were
checked for variance also contained a level of quality data.
Afterwards, genes showing at least a two-fold enrichment and a
median false discovery rate (FDR) and a Q-value threshold of 5%
after SAM statistical analysis [56], were chosen. For all
comparisons, we removed probes that corresponded to hypo-
thetic proteins, riken cDNAs, cDNA sequences and transcribed
loci because all of them are in silico predicted or not well
characterized just yet. This approach yielded a more accurate
identification of differences on global gene expression profiles,
making the final data sets more reliable for future validation. The
differentially expressed genes identified here were submitted to an
unsupervised hierarchical clustering analysis (HCL) [57] using the
average linkage algorithm and the Pearson correlation metric
distance to arrange genes and samples according to similarity in
patterns of gene expression.
Pathway analysis was generated by using the PANTHER
software. The binomial test was applied to determine whether
there was a statistical representation of genes (P,0.05) [58].
Accession Numbers
The raw microarray data are accessible from the ArrayExpress
(E-MEXP-2512 and E-MEXP-2517).
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Two-Step Real-Time RT-PCR
We next carried out studies to better evaluate the potential
impact, directly or indirectly, of DNA methylation and/or histone
deacetylation on the expression of specific genes that were selected
based on microarray results. To do this, mouse cell lines (melan-a,
4C, 4C112 and 4C11+) were grown and treated as described
above. Total cell RNA was extracted from 5AzaCdR and/or
TSA-treated and untreated (control) cell monolayers using TRIzol
reagent (Invitrogen). One microgram of RNA samples was reverse
amplified for cDNA synthesis with integrated removal of genomic
DNA contamination using QuantiTect Reverse Transcription Kit
(QIAGEN), according to manufacturer’s instructions.
The quality of the cDNA templates was checked by amplifying
the endogenous reference gene Actb. With the aim of determining
amplification efficiencies, we compared dilution series of reference
and target genes from a reference cDNA template. Serial dilutions
were amplified in two-step RT-qPCR and the Cq values obtained
were used to construct standard curves for Actb, Fblim1, Hspb1,
Serpine1 and Xist genes. The amplification efficiency of each gene
was determined as follows: E=10(-1/S) – 1, in which E corresponds
to the efficiency and S to the slope of the standard curve. Next,
equal amounts of each cDNA synthesized (200 ng/reaction) were
quantified by real-time PCR in a Corbett Rotor-Gene 6000
Detection System version 1.7 using a SYBR green PCR master
mix (QIAGEN) and a final concentration of specific forward and
reverse primers at 400 nM. PCR cycling conditions were set to 5
minutes at 95uC followed by 40 cycles of 5 seconds at 95uC and 10
seconds at 60uC. A signal for non-template control (NTC) was
evaluated as a control reaction since it enables detection of
contamination. Transcripts presenting Cq values $ 35 were
considered non-expressed. Because of the target(s) and the
endogenous reference gene were amplified with comparable
efficiencies (90%#E#110%), the relative quantification (RQ) of
the amplicons was calculated according to 2-DDCq method. Mouse
Actb was used as a single reference gene for normalizing cellular
mRNA data because of its more stable expression among the
previously untreated and treated cell lines than Gapdh gene (data
not shown).
To analyze the differences in the relative expression levels of
genes among the sample groups representing distinct phases of
melanocyte malignant transformation (melan-a, 4C, 4C112 and
4C11+), melan-a melanocyte lineage was taken as a reference
sample and its average value was set arbitrarily to 1. For
experiments involving treatment groups, untreated cell lines were
taken as reference samples, and their average values were set
arbitrarily to 1.
Human Studies
Human studies were performed with the aim of discussing the
potential application of our mouse findings in a way more closely
related to the pathogenesis of human melanomas. To do this, total
mRNA was isolated from FM305 human primary melanocytes
and metastatic melanoma cell lines (Mel-2, Mel-3, Mel-11, Mel-14
and Mel-33), and analyzed by two-step RT-qPCR, as described
for mouse experiments. In this case, we selected a panel comprised
by the genes CTCF, FBLIM1, HSPB1, NDRG2, NSD1, SERPINE1,
SRC and VDR to address their potential use as biomarkers in
identifying aggressive melanoma cells. To evaluate the differences
in the relative expression levels of genes between the two sample
groups (primary melanocytes and metastatic melanomas), the
human primary melanocyte was used as a reference sample, and
its average value was set arbitrarily to 1. For experiments involving
treatment groups, untreated cell lines were taken as reference
samples, and their average values were set arbitrarily to 1.
Unsupervised hierarchical clustering (Pearson correlation metric
distance; average linkage algorithm) and relevance network
prediction [59] of the genes validated in human primary
melanocytes and five early-passage metastatic melanoma cell lines
studied by RT-qPCR was performed using MeV software.
Additionally, a conventional RT-PCR approach was used to
assess the expression of XIST in two female human metastatic
melanoma cell lines (Mel-11 and Mel-33) using a recombinant
Platinum Taq DNA Polymerase (Invitrogen) and a final concen-
tration of specific forward and reverse primers at 10 mM. PCR
cycling conditions were set to 2 minutes at 94uC followed by 25
cycles of 30 seconds at 94uC, 30 seconds at 60uC, 30 seconds at
72uC and 7 minutes at 72uC.
Primer Design for RT-qPCR
To avoid amplification of genomic DNA, we designed mouse
(Integrated DNA Technologies Inc., Coralville, IA) and human
(Sigma-Aldrich) primer pairs flanking introns using IDT Primer-
Quest and Primer3 web interface. All primer sequences are listed
(Table S5).
Statistical Analysis
Statistical analysis of RT-qPCR results was performed by
Student’s t test or One Way ANOVA test followed by the post-hoc
Tukey. All statistics were carried out using GraphPad Prism
software version 5 for Windows (GraphPad). Error bars represent
SEM. The significance level was established at P,0.05. *P,0.05,
**P,0.01, ***P,0.001.
International Guidelines
The Minimum Information About a Microarray Experiment
(MIAME) as well as The Minimum Information for Publication of
Quantitative Real-Time PCR Experiments (MIQE) guidelines
were used for the better experimental design and interpretation of
microarray and qPCR results, respectively [60,61].
URLs
ArrayExpress can be found at http://www.ebi.ac.uk/
arrayexpress/. IDT PrimerQuest can be found at http://www.
idtdna.com/home/home.aspx. MeV can be found at http://www.
tm4.org/mev/. PANTHER software can be found at http://
www.pantherdb.org/tools. Primer3 web interface can be found at
http://frodo.wi.mit.edu/primer3/input.htm. RMAExpress can be
found at http://rmaexpress.bmbolstad.com.
Supporting Information
Figure S1 Karyotype Evolutionary Description. Overall
chromosomal rearrangements were shown in the representative
images of the metaphases derived from karyotypes of (A) 4C112
non-metastatic, and (B) 4C11+ metastatic melanoma cell lines. Left
panel: the raw image of a metaphase. Central panel: the classified image
of the metaphase. Right panel: the inverted DAPI-banded image of the
metaphase. Larger panel: the karyotype table of the metaphase.
(TIF)
Figure S2 Hierarchical Clustering of Samples and Dif-
ferentially Expressed Genes Upon 5-aza-29-deoxycytidine
Exposure Across the Melanoma Progression Spectrum.
(TIF)
Figure S3 Melanoma Stem Cell Markers Dynamically
Regulated during melan-a Malignant Transformation.
Green: Low expression; Red: High expression.
(PPT)
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Table S1 Transcripts Up-Regulated in melan-a Mela-
nocytes Following 5-aza-29-deoxycytidine Treatment
Identified by Genome-Wide Screening.
(DOC)
Table S2 Transcripts Up-Regulated in 4C Pre-Malig-
nant Melanocytes Following 5-aza-29-deoxycytidine
Treatment Identified by Genome-Wide Screening.
(DOC)
Table S3 Transcripts Up-Regulated in 4C112 Non-
Metastatic Melanoma Cells Following 5-aza-29-deoxycy-
tidine Treatment Identified by Genome-Wide Screening.
(DOC)
Table S4 Transcripts Up-Regulated in 4C11+ Metastat-
ic Melanoma Cells Following 5-aza-29-deoxycytidine
Treatment Identified by Genome-Wide Screening.
(DOC)
Table S5 Primers Used for Amplification by RT-qPCR.
(DOC)
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